. 2016 Nov 24;10(2):298. doi: 10.4081/oncol.2016.298

Table 1.

Hypertension related to available options in phase III studies in renal cell carcinoma.

Agent	Reference	Regimen	Patient, n	Hypertension (%)
Agent	Reference	Regimen	Patient, n	All grade	Grade 3/4
Sorafenib	Escudier et al.⁶	Placebo	452	2	<1
Sorafenib	Escudier et al.⁶	Sorafenib, 400 mg twice day	451	17	4
Sunitinib	Motzer et al.⁷	IFN	360	1	1
Sunitinib	Motzer et al.⁷	Sunitinib, 50 mg/day	375	24	8
Pazopanib	Sternberg et al.¹⁴	Placebo	145	10	<1
Pazopanib	Sternberg et al.¹⁴	Pazopanib	290	40	13
Pazopanib	Motzer et al.¹⁵	Sunitinib	553	41	15/<1
Pazopanib	Motzer et al.¹⁵	Pazopanib	557	46	15/<1
Pazopanib	Escudier et al.¹⁶	Sunitinib	148	26	9/0
Pazopanib	Escudier et al.¹⁶	Pazopanib	153	23	8/0
Bevacizumab	Escudier et al.¹⁷	Placebo + IFN	322	9	<1
Bevacizumab	Escudier et al.¹⁷	IFN + bevacizumab 10 mg/kg	327	26	3
Bevacizumab	Rini et al.^18,19	Placebo + IFN	349	28	0
Bevacizumab	Rini et al.^18,19	IFN + bevacizumab 10 mg/kg	366	4	11
Axitinib	Rini et al.⁸	Sorafenib	355	29	10.7/<1
Axitinib	Rini et al.⁸	Axitinib	359	40.4	15.3/<1
Cabozantinib	Motzer et al.²⁰	Everolimus	332	7	3
Cabozantinib	Motzer et al.²⁰	Cabozantinib	331	37	1

IFN, interferon.